Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06794996 · ClinicalTrials.gov registry record · Phase 2
Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidities
A Phase 2 study of Proteinuric Kidney Disease, sponsored by Vertex Pharmaceuticals Incorporated.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
- 20
- Study locations
NCT06794996: Recruiting Phase 2 study of Proteinuric Kidney Disease, sponsored by Vertex Pharmaceuticals Incorporated.
NCT06794996 is a Phase 2 study of Proteinuric Kidney Disease that is actively recruiting participants, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 45 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (66% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06794996, a Phase 2 study of Proteinuric Kidney Disease, is actively recruiting participants, sponsored by Vertex Pharmaceuticals Incorporated.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to evaluate the efficacy, safety, and tolerability of Inaxaplin (IXP) in participants with proteinuric APOL1- mediated kidney disease (AMKD).
Conditions Studied
Interventions
- DRUG Inaxaplin
Study Locations (20)
Georgia
- Renal Associates, LLC - Columbus
- Georgia Nephrology - Decatur - Decatur
- Javara Inc./Privia Medical Group Georgia, LLC - Fayetteville - Fayetteville
- Georgia Nephrology - Lawrenceville
- Javara Inc. /Privia Medical Group Georgia, LLC - Savannah - Savannah
Florida
- Foundation for Sickle Cell Disease Research, LLC - Hollywood
- South Florida Research Institute - Lauderdale Lakes
- Schiff Center for Liver Diseases - Miami
- CTR Oakwater, LLC - Orlando
Louisiana
- Renal Associates of Baton Rouge - Baton Rouge
- LCMC Health - Metairie
- Ochsner Medical Center - New Orleans - Nephrology - New Orleans
- Northwest Louisiana Nephrology, LLC - Shreveport - Shreveport
Mississippi
- Nephrology Associates, P.C. - Columbus
- Nephrology and Hypertension Associates, LTD - Tupelo
New Jersey
- Saint Michael's Medical Center - Peter Ho Memorial Clinic - Newark
- Rutgers Doctors Office Center - Newark
Alabama
- Nephrology Consultants, LLC - Huntsville
Maryland
- Javara Inc./Privia Medical Group, LLC MidAtlantic-Silver Spring, MD - Silver Spring
Nevada
- DaVita Clinical Research - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2025-02-04 |
| Est. Completion | 2026-12-30 |
| Phase | Phase 2 |
What NCT06794996 shows while recruiting
NCT06794996 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (66% lower).
The record links to 1 condition, with Proteinuric Kidney Disease appearing as the primary indexed condition, and to 1 intervention - of which Inaxaplin is the first listed.
NCT06794996 names 20 study sites across 8 states, led by Georgia, Florida, Louisiana.
Frequently Asked Questions
What is clinical trial NCT06794996 about?
NCT06794996 is a clinical study titled "Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidities". The purpose of the study is to evaluate the efficacy, safety, and tolerability of Inaxaplin (IXP) in participants with proteinuric APOL1- mediated kidney disease (AMKD).
What is the current status of trial NCT06794996?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2025-02-04. Estimated completion is 2026-12-30.
What conditions does trial NCT06794996 study?
This clinical trial studies the following conditions: Proteinuric Kidney Disease.
What interventions are being tested in trial NCT06794996?
The interventions under investigation include: Inaxaplin (DRUG).
Who is sponsoring clinical trial NCT06794996?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06794996 being conducted?
This trial has 20 study locations across Alabama, Florida, Georgia, Louisiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Proteinuric Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06794996's enrollment target sits among peer trials
45 1296th of 2000 higher than 680 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI